



Singapore  
General Hospital  
SingHealth



# Beyond Clotting Time – Clot Waveform Analysis (CWA)

DR CHUEN WEN TAN  
CONSULTANT  
DEPARTMENT OF HAEMATOLOGY  
SINGAPORE GENERAL HOSPITAL


FELLOW  
ANZAC RESEARCH INSTITUTE  
HAEMATOLOGY, CONCORD  
HOSPITAL




# Outline

- Background
- Clinical applications of CWA


# Photo-Optical Method of Clotting Time Measurement




# New Utility of An Old Test




# Understanding CWA





# CWA Parameters



↑ CWA Parameters

↑ Coagulability

# Growing List of Analyzers with CWA Function

**Table S 1 Coagulation analyzers and APTT reagents for Clot Waveform Analysis**


**Coagulation analyzer**

CA-7000	Sysmex
CS-5100	Sysmex
CS-2000i, CS-2100i	Sysmex
CA-1500	Sysmex
BCS	Siemens
BCT	Siemens
ACL-Top 700	IL
ACL-Top 500 CTS	IL
ACL-Top 300 CTS	IL
ACL-Advance	IL
ACL-FUTURA	IL
ACL-ELITE pro	IL
ACL-7000	IL
CD-X	Dia Med
MDA-II	Trinity
Coapresta2000	Shimazu



# Applications of CWA

# Early Disseminated Intravascular Coagulation (DIC) marker – Biphasic Waveform




- 1187 patients admitted to ICU
- BPW preceded DIC diagnosis by 18hours
- BPW is due to formation of a precipitate containing VLDL and CRP in the presence of  $Ca^{++}$  → changes turbidity on recalcification of plasma

# APTT-BASED CLOT WAVEFORM ANALYSIS IN VARIOUS INFECTIONS

- Retrospective study
- Subjects:
  - **Controls subject:** Patients admitted for elective orthopedic, urology surgery with pre-operative screening aPTT
  - **Infection subject:** Patients admitted with various infection (proven by cultures/molecular tests) who had aPTT done within 48 hours of admission:
    1. Patients with bacterial infection
    2. Patients with dengue infection
    3. Patients with viral respiratory tract infection
- Exclusion criteria: Subjects on anticoagulant, with active thrombosis and cancer, DIC

# Different infections, different CWA parameters: Increased CWA results in bacterial infection and reduced CWA results in dengue infection




Bacterial infection (n= 52)	Dengue infection (n= 36)	Other viral infection (n= 13)	Control (n= 112)
-----------------------------	--------------------------	-------------------------------	------------------



A

B

C



1-way Anova with Bonferoni correction  
Adjusted for age/gender/race

# Application of CWA in Bleeding Disorders

ORIGINAL ARTICLE

## Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

K. NOGAMI,\* T. MATSUMOTO,\*\*† Y. TABUCHI,‡ T. SOEDA,§ N. ARAI,‡ T. KITAZAWA§ and M. SHIMA\*†

## Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies

Naoki Tokunaga<sup>a</sup>, Chihiro Inoue<sup>a</sup>, Toshiyuki Sakata<sup>b</sup>, Kumiko Kagawa<sup>c</sup>, Masahiro Abe<sup>c</sup>, Norimichi Takamatsu<sup>a</sup>, Takayuki Nakao<sup>a</sup> and Toshio Doi<sup>d</sup>

<sup>a</sup>Division of Medical Technology, Tokushima University Hospital, Tokushima, <sup>b</sup>IL Japan Co., Ltd., Tokyo, <sup>c</sup>Department of Hematology, Tokushima University Hospital, Tokushima and <sup>d</sup>Clinical Laboratory Tokushima, University Hospital, Tokushima, Japan

## Haemophilia


Utility of global hemostatic assays in haemophilia patient

I. Q. Wu □, C. W. Tan, W. H. Wong, H. J. Ng

## Clot waveform analysis in patients with haemophilia A


T. Siegemund<sup>1</sup>; U. Scholz<sup>2</sup>; R. Schobess<sup>2</sup>; A. Siegemund<sup>2</sup>

<sup>1</sup>The Scripps Research Institute, Department of Molecular and Experimental Medicine, Roon Research Center for Arteriosclerosis and Thrombosis, La Jolla, California, USA; <sup>2</sup>MVZ Lab Dr. Reising-Ackermann and Colleagues, Center of Coagulation Disorders, Leipzig, Germany

WILEY Haemophilia 

ORIGINAL ARTICLE  
Laboratory science

Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A

T. Matsumoto<sup>1,2</sup> | K. Nogami<sup>1</sup>  | Y. Tabuchi<sup>3</sup> | K. Yada<sup>1</sup> | K. Ogiwara<sup>1</sup> | H. Kurono<sup>3</sup> | N. Arai<sup>3</sup> | M. Shima<sup>1</sup>

## Application of CWA in Bleeding Disorders

ORIGINAL ARTICLE *Laboratory science*

New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients

M. MILOS,\* D. COEN HERAK,\* S. ZUPANCIC-SALEK† and R. ZADRO‡

\*Department of Laboratory Diagnostics; †Department of Medicine University Hospital Centre Zagreb; and ‡Department of Laboratory Diagnostics University Hospital Centre Zagreb and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia

Thromb Haemost 2002; 87: 436–41

© 2002 Schattauer GmbH, Stuttgart

## The Utility of activated Partial Thromboplastin Time (aPTT) Clot Waveform Analysis in the Investigation of Hemophilia A Patients with very Low Levels of Factor VIII Activity (FVIII:C)

Midori Shima<sup>1</sup>, Tomoko Matsumoto<sup>1</sup>, Kazuyoshi Fukuda<sup>1</sup>, Youko Kubota<sup>1</sup>, Ichiro Tanaka<sup>1</sup>, Katumi Nishiya<sup>1</sup>, Alan R. Giles<sup>2</sup>, Akira Yoshioka<sup>1</sup>

*Journal of Thrombosis and Haemostasis*, 4: 377–384

ORIGINAL ARTICLE

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay

T. MATSUMOTO,\* M. SHIMA,\* M. TAKEYAMA,\* K. YOSHIDA,\* I. TANAKA,\* Y. SAKURAI,\* A. R. GILES† and A. YOSHIOKA\*

# Application in Bleeding Disorders

- Detection of low levels of factor VIII and IX activities
- Management of haemophilia
  - Factor replacement
  - Bypassing agents including emicizumab





# Application of CWA in Thrombotic Disorders



# THE ASSOCIATION OF CWA PARAMETERS WITH ACUTE VENOUS THROMBOEMBOLISM (VTE)

- Retrospective study
- Subjects:
  - **Controls subject:** Patients admitted for elective orthopedic, urology surgery with pre-operative screening aPTT
  - **Patients with acute VTE:** Patients with acute VTE prior to initiation of anticoagulants

# CWA parameters are significantly elevated in acute venous thromboembolism



Patients (n) = 45

Controls (n) = 111

aPTT results similar  
between the groups

2-sample independent T-test  
Adjusted for age/gender/race

# Elevated CWA are strongly associated with venous thromboembolism

Parameter	Unadjusted			Adjusted (for age, gender, ethnicity)		
	Odds ratio	95% CI	p-value	Odds ratio	95% CI	p-value
APTT ratio $\leq 0.9$	1.790	0.76 - 4.20	0.182	2.03	0.83 - 4.95	0.119
<b>Min1 &gt;reference interval</b>	<b>8.00</b>	<b>3.59 - 17.83</b>	<b>* &lt;0.001</b>	<b>8.37</b>	<b>3.63 - 19.26</b>	<b>* &lt;0.001</b>
<b>Min2 &gt;reference interval</b>	<b>5.24</b>	<b>2.48 - 11.07</b>	<b>* &lt;0.001</b>	<b>5.93</b>	<b>2.68 - 13.11</b>	<b>* &lt;0.001</b>
<b>Max2 &gt;reference interval</b>	<b>4.75</b>	<b>2.15 - 10.48</b>	<b>* &lt;0.001</b>	<b>4.99</b>	<b>2.20 - 11.34</b>	<b>* &lt;0.001</b>
<b>Delta change &gt;reference interval</b>	<b>18.55</b>	<b>6.36 - 54.15</b>	<b>* &lt;0.001</b>	<b>19.09</b>	<b>6.31 - 57.69</b>	<b>* &lt;0.001</b>

EHA 2018

CWA as potential markers for hypercoagulability

Ruberto et al (2018)

# Comparability of CWA Results

# Multicentre Study of Normal Controls

- 6 centres (at least 40 samples from each centre)
- 3 reagents: Actin FS, Actin FSL, Pathromtin SL (approximately 200 samples for each reagent)
- Analyzer: Sysmex CS2100i

ACTIN FS:

Normal ranges of CWA comparable across the labs

ACTIN FSL:

Normal ranges of CWA parameters are comparable between the labs

Different aPTT Reagents: CWA data are dissimilar



# Possibility of combining CWA data and future multicentre studies

- Combine CWA data from different labs
  - Coagulation analyser
  - aPTT reagents

} Standardised

# CWA: Advantages vs Disadvantages

## Advantages

- Easily performed/automated
- Widely available
- Routine reagents
- Low cost

## Disadvantages

- Whole blood/platelet rich plasma samples not suitable
- Data on influence of preanalytical variables lacking

# Conclusions

- Global haemostatic assay
  - Wide availability
  - Automated
  - Cheap
- Potential applications in:
  - Bleeding disorders
  - Thrombotic disorders
  - Infection/Sepsis



# Acknowledgement

- Singapore General Hospital
  - Department of Haematology
    - Dr Heng Joo Ng
    - Dr Lai Heng Lee
  - Haematology Laboratory
    - Dr Wan Hui Wong
  
- All the patients and blood donors

# Thank You